Limits...
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus

Correlation between PCDH17 methylation and progression-free survival in ccRCC patients. Patients with PCDH17 methylation showed significantly shorter progression-free survival than patients without (log-rank test, P=0.0002).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588677&req=5

f2-medscimonit-21-2870: Correlation between PCDH17 methylation and progression-free survival in ccRCC patients. Patients with PCDH17 methylation showed significantly shorter progression-free survival than patients without (log-rank test, P=0.0002).

Mentions: To examine if PCDH17 is a significant predictor of patients’ outcome after surgery, Kaplan-Meier curves and log-rank tests were performed. We found that patients with methylated PCDH17 had significantly shorter progression-free time and 5-year overall survival time than patients with unmethylated PCDH17. These findings are shown in Figures 2 and 3. To further determine the predictive value of PCDH17 methylation in ccRCC patients, the Univariate and Multivariate Cox proportional hazard model analysis was carried out, and the parameters that were significant risk factors in univariate analysis were entered into multivariate analysis. The results suggested that PCDH17 methylation is an independent prognostic factor for progression-free survival and 5-year overall survival of ccRCC patients. The results are shown in Tables 4 and 5.


Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

Correlation between PCDH17 methylation and progression-free survival in ccRCC patients. Patients with PCDH17 methylation showed significantly shorter progression-free survival than patients without (log-rank test, P=0.0002).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588677&req=5

f2-medscimonit-21-2870: Correlation between PCDH17 methylation and progression-free survival in ccRCC patients. Patients with PCDH17 methylation showed significantly shorter progression-free survival than patients without (log-rank test, P=0.0002).
Mentions: To examine if PCDH17 is a significant predictor of patients’ outcome after surgery, Kaplan-Meier curves and log-rank tests were performed. We found that patients with methylated PCDH17 had significantly shorter progression-free time and 5-year overall survival time than patients with unmethylated PCDH17. These findings are shown in Figures 2 and 3. To further determine the predictive value of PCDH17 methylation in ccRCC patients, the Univariate and Multivariate Cox proportional hazard model analysis was carried out, and the parameters that were significant risk factors in univariate analysis were entered into multivariate analysis. The results suggested that PCDH17 methylation is an independent prognostic factor for progression-free survival and 5-year overall survival of ccRCC patients. The results are shown in Tables 4 and 5.

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus